MARKET

SMMT

SMMT

Summit Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.010
-0.050
-4.72%
Opening 15:47 05/18 EDT
OPEN
1.020
PREV CLOSE
1.060
HIGH
1.030
LOW
1.000
VOLUME
40.28K
TURNOVER
15.86K
52 WEEK HIGH
8.70
52 WEEK LOW
1.010
MARKET CAP
99.10M
P/E (TTM)
-1.0439
1D
5D
1M
3M
1Y
5Y
Summit Therapeutics GAAP EPS of -$0.22, revenue of $0.25M
Summit Therapeutics press release (NASDAQ:SMMT): Q1 GAAP EPS of -$0.22. Revenue of $0.25M (+31.6% Y/Y).
Seekingalpha · 6d ago
Summit Therapeutics Q1 EPS $(0.22) Down From $(0.21) YoY, Sales $250.00K Up From $192.00K YoY
Summit Therapeutics (NASDAQ:SMMT) reported quarterly losses of $(0.22) per share. This is a 4.76 percent decrease over losses of $(0.21) per share from the same period last year. The company reported $250.00 thousand in
Benzinga · 6d ago
-- Earnings Flash (SMMT) SUMMIT THERAPEUTICS Posts Q1 Revenue $250,000
MT Newswires · 05/11 16:44
What Kind Of Shareholders Hold The Majority In Summit Therapeutics Inc.'s (NASDAQ:SMMT) Shares?
The big shareholder groups in Summit Therapeutics Inc. ( NASDAQ:SMMT ) have power over the company. Generally speaking...
Simply Wall St. · 05/08 13:44
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Benzinga · 04/29 12:16
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Benzinga · 04/25 12:29
Summit Therapeutics Inc. (NASDAQ:SMMT) insiders placed bullish bets worth US$62m in the last 12 months
Over the last year, a good number of insiders have significantly increased their holdings in Summit Therapeutics Inc...
Simply Wall St. · 04/10 12:36
Analyzing Summit Therapeutics Inc's Short Interest
Summit Therapeutics Inc's (NASDAQ:SMMT) short percent of float has risen 50.18% since its last report. The company recently reported that it has 1.06 million shares sold short, which is 4.19% of all regular shares that are available for trading.
Benzinga · 03/21 13:15
More
No Data
Learn about the latest financial forecast of SMMT. Analyze the recent business situations of Summit Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

100.00%Strong Buy
0.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average SMMT stock price target is 5.00 with a high estimate of 5.00 and a low estimate of 5.00.
High5.00
Average5.00
Low5.00
Current 1.010
EPS
Actual
Estimate
-1.10-0.83-0.55-0.28
  • 0
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Institutional Holdings
Institutions: 64
Institutional Holdings: 16.13M
% Owned: 16.44%
Shares Outstanding: 98.12M
TypeInstitutionsShares
Increased
16
459.78K
New
9
121.89K
Decreased
20
435.08K
Sold Out
7
52.12K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.26%
Pharmaceuticals & Medical Research
-2.20%
Key Executives
Chairman/Chief Executive Officer/Executive Director
Robert Duggan
Chief Financial Officer
Michael Donaldson
Chief Operating Officer/Director
Mahkam Zanganeh
Chief Scientific Officer
David Powell
Director
Kenneth Clark
Director
Urte Gayko
Independent Director
Ujwala Mahatme
Non-Executive Independent Director
Rainer Erdtmann
Non-Executive Independent Director
Manmeet Soni
No Data
No Data
About SMMT
Summit Therapeutics Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing novel antibiotics for serious infectious diseases. Its lead CDI product candidate is ridinilazole is an orally administered small molecule antibiotic. The Company's preclinical candidates include SMT-738, from the DDS-04 series for development in the fight against multidrug-resistant infections, specifically carbapenem-resistant Enterobacteriaceae (CRE) infections. The Company is conducting a Phase III clinical program focused on the infectious disease C. difficile infection (CDI). The Company is also seeking to expand its product candidate portfolio through the development of a new mechanism, precision antibiotics using its proprietary Discuva Platform.

Webull offers kinds of Summit Therapeutics Inc stock information, including NASDAQ:SMMT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SMMT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SMMT stock methods without spending real money on the virtual paper trading platform.